medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2021, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (2)

Inflammation markers determination in sickle cell trait (Hb AS)

Language: Spanish
References: 12
Page: 1-4
PDF size: 262.62 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Svarch E, Machín S. Epidemiología de la drepanocitosis en países de América Latina y del Caribe. Rev Cub Hemat Inmunol Hemoter.2020;36(2):1-14.

  2. Ajayi A. Leslie A. Should the sickle cell trait be reclassified as a disease state? Eur J Int Med. 2005;16(6):463. DOI: 10.1016/j.ejim.2005.02.010

  3. Roach ES. Sickle cell trait: innocent until proven guilty. Arch Neurol. 2005 Nov;62(11):1781-1782. DOI: https://10.1001/archneur.62.11.1781

  4. Hyacinth I, Carty C, Seals S. Association of sickle cell trait with ischemic stroke among African Americans. A meta-analysis. JAMA Neurol. 2018;75(7):802-7. DOI: https://doi:10.1001/jamaneurol.2018.0571

  5. Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am J Med. 2009;122(6):507–12. DOI: https://doi10.1016/j.amjmed.2008.12.020

  6. Folsom AR, Tang W, Roetker NS. Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost. 2015;13:2-9.

  7. Naik RP, Derebail VK, Grams ME.. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 2014;312:2115-25.

  8. Tripette J, Hardy-Dessources MD, Romana M. Exercise-related complications in sickle cell trait. Clin Hemorheol Microcirc. 2013; 55:29-37.

  9. Baskurt OK, Meiselman HJ, Bergeron MF. Sickle cell trait should/should not be considered asymptomatic and as a benign condition during physical activity. J Appl Physiol. 2007;103:2143-44 10. Stockley RA. Alpha1-antitrypsin review. Clin Chest Med.2014; 35:39-50. DOI: https://doi:10.1016/j.ccm.2013.10.001

  10. Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol. 1998; 61:49–54. DOI: 10.1111/j.1600-0609.1998.tb01060.x

  11. Carvalho M, Araujo-Santos J, Rocha L, Cerqueira B, Luz N, Lyra I, et al. Inflammatory mediators in sickle cell anaemia highlight the difference between steady state and crisis in paediatric patients. Br J Haematol 2018;182:909-43 DOI: https://doi.org/10.1111/bjh.14896

  12. Sarray S, Saleh L, Saldanha F, Al-Habboubi H, Mahdi N, Almawi Y. Serum IL-6, IL-10 and TNFα levels in pediatric sickle cell disease patients during vasooclusive crisis and steady state condition. Cytokine.2015;72(1):43-7. DOI: 10.1016/j.cyto.2014.11.030




2020     |     www.medigraphic.com